CAR-T cell therapy for breast cancer: Current status and future perspective

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Metastatic breast cancer (MBC) remains largely incurable, often developing resistance to standard treatments.
• Cellular immunotherapy (CI), specifically chimeric antigen receptor (CAR)-T cells, offers a promising therapeutic avenue for MBC.
• Current CAR-T cell therapy for breast cancer faces limitations due to scarce tumor-specific antigens and an immunosuppressive tumor microenvironment.

Purpose of the Study:

• To provide an updated overview of preclinical and clinical data on CAR-T cell therapy in breast cancer.
• To discuss current constraints and propose strategies for advancing CAR-T cell therapy in breast cancer.
• To outline a future trajectory for CAR-T cells in breast cancer treatment.

Main Methods:

• Literature review of preclinical and clinical studies on CAR-T cell therapy for breast cancer.
• Analysis of existing challenges, including antigen scarcity and tumor microenvironment.
• Exploration of innovative strategies to enhance CAR-T cell efficacy and safety.

Main Results:

• CAR-T cell therapy has shown potential but requires overcoming significant hurdles in breast cancer.
• Strategies like synthetic biology for antigen targeting, logic-gated CARs, and armored CARs can improve specificity and combat immunosuppression.
• Enhancements in T cell homing, safety regulation, and manufacturing processes are crucial for broader applicability.

Conclusions:

• Advancements in CAR-T cell technology are addressing key limitations in breast cancer treatment.
• Optimized CAR-T cell therapies hold the potential to overcome antigen escape and T cell exhaustion.
• CAR-T cell therapy is evolving towards becoming a standard treatment modality for breast cancer.